- Dec 1, 2020
NCT04268498: Phase2 - Daratumumab, Carfilzomib, Lenalidomide, Dex NDMM Multiple Myeloma (ADVANCE)
The ADVANCE trial Dara-KRd KRd VRd NCT04268498: A Study of Daratumumab, Carfilzomib, Lenalidomide, and Dexamethasone in Patients With...
945
- Dec 1, 2020
NCT04352205: Phase 2: Daratumumab-Based Therapy for NDMM Multiple Myeloma with Kidney failure
NCT04352205: Phase 2: Daratumumab-Based Therapy for the Treatment of Newly Diagnosed Multiple Myeloma With Kidney Failure NCT04352205:...
37
- Dec 1, 2020
NCT04459416: Phase 3: Managing Pain and Symptom Burden Caused by Chemotherapy in Myeloma or Lymphoma
OPTIMAL-HiChemo NCT04459416: Phase 3: Managing Pain and Symptom Burden Caused by Chemotherapy in People With Myeloma or Lymphoma...
35
- Dec 1, 2020
NCI - National Cancer Institute : How Monoclonal Antibodies Treat Cancer?
How Monoclonal Antibodies Treat Cancer? Daratumumab is a monoclonal antibody against CD38, molecules present on myeloma cancer cells....
197
- Dec 1, 2020
NYC-Miami Myeloma MRD 2020 Virtual Meeting, 8th of October 2020
VJHemOnc was official media partner of the NYC-Miami Myeloma MRD 2020 Virtual Meeting which took place on the 8th of October 2020 and was...
73
- Dec 1, 2020
EHA25 Virtual : Congress of the European Hematology Association - June 11 - 21, 2020
EHA25 Virtual : Congress of the European Hematology Association, June 11 - 21, 2020 EHA25 Virtual : Congress of the European Hematology...
126